Figure 1From: Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone Graphical representation of tumor marker and alkaline phosphatase over time. A: Tumor marker CA 27–29 levels after each treatment with radium-223 (Ra-223) dichloride, B: Serial alkaline phosphate (ALP) levels after each treatment with Ra-223 dichloride.Back to article page